| Gene symbol | IGHG1 | Synonyms | None | Type of gene | other |
| Chromosome | 14 | Map location | 14q32.33 | dbXrefs | |
| Description | immunoglobulin heavy constant gamma 1 (G1m marker) | ||||
| GTO ID | GTC2546 |
| Trial ID | NCT04683939 |
| Disease | Stomach Cancer | Gastroesophageal Adenocarcinoma | Esophageal Carcinoma | Cholangiocarcinoma | Pancreatic Cancer | Biliary Tract Cancer |
| Altered gene | IGHG1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT141 |
| Phase | Phase1|Phase2 |
| Recruitment status | Terminated |
| Title | Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors |
| Year | 2022 |
| Country | United States|Canada |
| Company sponsor | BioNTech SE |
| Other ID(s) | BNT141-01|2022-001843-25 |
| Vector information | |||
|
|||
| Cohort1: BNT141 | |||||||||
|
|||||||||
| Cohort2: BNT141_Nab-paclitaxel_gemcitabine | |||||||||
|
|||||||||